Its main ingredient, tirzepatide, targets two hormones that can slow down food digestion. Similar drugs approved for use in ...
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...
1d
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
Nvidia topping Apple as the most valuable company in the world and joining the Dow Jones Industrial Average. Why Novo Nordisk ...
Novo Nordisk (NVO) has released an update. Novo Nordisk has announced a significant transaction under its 2024 share repurchase program, acquiring 6.31 million B shares from Novo Holdings for DKK 4.74 ...
MT Newswires on MSN1d
Novo Nordisk Earnings Ease Investor Concerns, Put Focus on New Obesity Drug TrialNovo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...
A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback